Molgramostim Inhalation Solution

Name: Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Product comparison
Published: 2026-09-14T15:39:06-04:00

Autoimmune pulmonary alveolar proteinosis

Manufacturer: Savara
Regulatory submission: BLA resubmitted December 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Product comparison

2 evidence topics · 2 sources

Sargramostim and molgramostim: limits of indirect comparisons

“these results are exploratory and do not prove clinical equivalency between sargramostim and molgramostim” (opens the source at this quote in a new tab)
“No significant differences were found for six-minute walk distance” (opens the source at this quote in a new tab)

Daratumumab in refractory disease: case report

“One year post completion of Daratumumab, the patient remained in remission with clinical and radiological improvement.” (opens the source at this quote in a new tab)